N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide

N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide
Trade Name
Orphan Indication Acute myeloid leukemia
USA Market Approval USA
USA Designation Date 2008-02-01 00:00:00
Sponsor Mirati Therapeutics, Inc.;9363 Towne Center Drive, Suite 200;San Diego, California, 92121
Related Access Program
Children’s Hospital Los Angeles – Acute myeloid leukemia Jazz Pharmaceuticals – Secondary AML Celator Pharmaceuticals – Secondary AML University of California, San Francisco – Acute myeloid leukemia Emory University – Acute myeloid leukemia